Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (NASDAQ: MBOT) has acquired the assets of Nitiloop Ltd., which includes the FDA-cleared NovaCross™ family of microcatheters. This acquisition aims to enhance the LIBERTY® Robotic System's capabilities, promoting robotics in endovascular procedures. The NovaCross™ devices are designed for navigating chronic total occlusions (CTO) and will potentially standardize procedures while increasing access to robotic technology globally. The move opens a significant growth opportunity in the $500 million CTO market, aligning with Microbot's strategic mission for global accessibility in medical technologies.
Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of Dr. David C. Madoff to its Scientific Advisory Board. Dr. Madoff, a renowned interventional radiologist from Yale School of Medicine, brings extensive clinical research experience that is expected to enhance the company's efforts in advancing the LIBERTY® Robotic System through regulatory phases. His expertise in interventional oncology and numerous publications position him to significantly contribute to Microbot's mission of improving clinical outcomes and accessibility in healthcare.
Microbot Medical (NASDAQ: MBOT) has appointed Dr. Ripal T. Gandhi to its Scientific Advisory Board. Dr. Gandhi, an interventional oncologist with expertise in minimally invasive treatments, aims to enhance the development of Microbot's LIBERTY Robotic System. His extensive experience includes over 100 robotic cases and innovation in interventional robotics, providing valuable insights to the team. This recruitment aligns with Microbot's strategy to strengthen its advisory network and advance its micro-robotic technologies, aimed at improving patient outcomes.
Microbot Medical Inc. (Nasdaq: MBOT) has announced that renowned interventional radiologist Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board. Dr. Vidal, recognized for his expertise in embolization techniques, aims to leverage his experience to advance the LIBERTY® Robotic System. His previous successful pre-clinical trial for the system has inspired this collaboration, which seeks to facilitate regulatory processes and global commercialization. CEO Harel Gadot expressed confidence in Dr. Vidal's contributions towards achieving clinical and financial goals with the system.
Microbot Medical Inc. (NASDAQ: MBOT) announced key developments for its LIBERTY® Robotic System during the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. CEO Harel Gadot highlighted the commencement of the GLP pre-clinical trial and provided an overview of the company's progress and future plans. Microbot Medical focuses on advanced micro-robotic technologies targeted at improving patient outcomes and accessibility in medical treatments. The presentation is available for viewing on their official website.
Microbot Medical Inc. (Nasdaq: MBOT) has launched its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a renowned MedTech research institute. This trial marks a significant milestone in the company’s journey toward regulatory approvals. CEO Harel Gadot believes that successful feasibility studies will enable them to meet the trial's endpoints and further pursue regulatory approvals in the surgical robotics sector, particularly in endovascular applications. This move underscores Microbot's focus on innovative micro-robotic technologies aimed at enhancing clinical outcomes.
Microbot Medical (NASDAQ: MBOT) announced the appointment of Dr. Sebastian Flacke to its Scientific Advisory Board, enhancing its expertise in the endovascular space. Dr. Flacke, a pioneer in robotic solutions and interventional radiology, will guide the company through crucial regulatory processes and commercialization efforts for the LIBERTY® Robotic System. This system aims to be the first fully disposable endovascular robotic platform, improving patient access globally. CEO Harel Gadot emphasized Dr. Flacke's innovative contributions, signaling strong leadership for future developments.
Microbot Medical Inc. (Nasdaq: MBOT) has received two Design Patent Applications grants from the European Patent Office, enhancing its LIBERTY® Robotic System’s IP portfolio. This recognition underscores the innovative aspects of the LIBERTY Robotic System, providing a sustainable competitive advantage in the medical device sector. CEO Harel Gadot emphasized that expanding their IP will support their vision for broader accessibility to robotic technologies, benefiting physicians and patients alike.
Microbot Medical (NASDAQ: MBOT) has shipped multiple LIBERTY Robotic System devices for a GLP pre-clinical trial, scheduled to start this month, at a leading research laboratory. This initiative is part of the company's preparations for FDA and CE Mark submissions. CEO Harel Gadot expressed optimism about their collaboration with top experts, indicating that the trial results will validate prior successful animal studies.
Microbot Medical Inc. (Nasdaq: MBOT) will present its Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons from September 6-8, 2022, in Jerusalem, Israel. The presentation will be led by Dr. Gustavo Rajz during the Neuro Innovation and Start-Up Symposium on September 7. The SCS aims to prevent cerebrospinal fluid obstructions in patients with hydrocephalus and has received FDA approval for an Early Feasibility Study. For further inquiries or demonstrations, contact the company via email.